Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01608958
Other study ID # 3000
Secondary ID
Status Completed
Phase N/A
First received May 29, 2012
Last updated March 25, 2016
Start date May 2012
Est. completion date December 2012

Study information

Verified date March 2016
Source Gynuity Health Projects
Contact n/a
Is FDA regulated No
Health authority Vietnam: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The study will evaluate whether prophylactic oxytocin administered in the third stage of labor via IV infusion results in a lower mean blood loss compared to IM injection.


Description:

The study will compare the effect of IV infusion and IM oxytocin administration on the proportion of women who experience blood loss greater than or equal t 350 ml, the proportion of women who experience blood loss greater than or equal to 500 ml, side effects, adverse events and change in hemoglobin pre- to post-delivery. It will also assess whether a bleeding history questionnaire can identify women at risk for excessive bleeding and help to define the distribution of bleeding scores among women with and without excessive bleeding.


Recruitment information / eligibility

Status Completed
Enrollment 653
Est. completion date December 2012
Est. primary completion date November 2012
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group N/A and older
Eligibility Inclusion Criteria:

- All women who present in active labor for a live birth at the study hospital will be considered for participation in the study

Exclusion Criteria: Women who are:

- Planned or transferred for delivery via Cesarean section

- Not delivering a live birth

- Unable to provide informed consent due to mental impairment, distress during labor or other reason

- Unwilling and/or unable to respond to questionnaires about background characteristics and/or bleeding history.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Drug:
Oxytocin
10 IU oxytocin in 500 ml infusion
Oxytocin
10 IU oxytocin IM injection

Locations

Country Name City State
Ecuador Hospital Gineco-Obstétrico Isidro Ayora Quito
Turkey SB Etlik Zübeyde Hanim Kadin Hastaliklari Egitim ve Arastirma Hastanesi Ankara
Vietnam Huong Vuong Hospital Ho Chi Minh City

Sponsors (4)

Lead Sponsor Collaborator
Gynuity Health Projects Center for Research and Consultancy in Reproductive Health, Huong Vuong Hospital, MOH Etlik Zubeyde Hanim Women's Health Training and Research Hospital

Countries where clinical trial is conducted

Ecuador,  Turkey,  Vietnam, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean blood loss (ml) minimum of 1 hour after delivery of baby No
Secondary Proportion of women who bleed greater or equal to 350 ml, 500 ml and 1000 ml minimum of 1 hour after delivery of baby No
Secondary Change in hemoglobin from pre-delivery to postpartum Post-delivery hemoglobin using a Hemocue® Hemoglobin machine + cuvette will be taken at least 24 after delivery and before the woman leaves the facility. If the woman has received IV fluids, hemoglobin will be measured at least 12 hours after removal of the IV prior to discharge. 12-24 hours after delivery No
Secondary Time to placental delivery minimum of 1 hour after delivery of baby No
Secondary Administration of additional oxytocin, other uterotonics, or other interventions such as blood transfusion and hysterectomy minimum of 1 hour after delivery of baby No
Secondary Side effects 1 hour postpartum 1 hour postpartum No
Secondary Bleeding scores calculated from a standardized questionnaire administered on arrival to labor ward arrival to labor ward No
See also
  Status Clinical Trial Phase
Completed NCT03434444 - In Vitro Optimization of Oxytocin-induced Myometrial Contractility by Propranolol N/A
Terminated NCT01980173 - Medico-economic Comparison of Postpartum Hemorrhage Management Using the Bakri Balloon and Standard Care N/A
Not yet recruiting NCT06033170 - Celox™ PPH for Reaching Haemostasis in Patients With Postpartum Hemorrhage N/A
Not yet recruiting NCT02319707 - Management of the Third Stage of Labor Phase 3
Completed NCT02163616 - Treatment of Postpartum Hemorrhage With Misoprostol: Fever Study Phase 3
Recruiting NCT01600612 - Oxytocin, Carbetocin and Misopristol for Treatment of Postpartum Hemorrhage: A Multicentric Randomized Trial N/A
Completed NCT02079558 - Efficacy of Oxytocin vs. Carbetocin in Prevention of Postpartum Hemorrhage After Cesarean Section Phase 2
Withdrawn NCT01108302 - Effectiveness, Safety and Feasibility of Auxiliary Nurse Midwives' (ANM) Use of Oxytocin in Uniject™ to Prevent Postpartum Hemorrhage in India N/A
Completed NCT00097123 - RCT of Misoprostol for Postpartum Hemorrhage in India N/A
Completed NCT02883673 - Safety and Effectiveness of the Jada System in Treating Primary Postpartum Hemorrhage N/A
Completed NCT02542813 - Safety, Tolerability and Pharmacokinetics (PK) Study of Oxytocin (GR121619) Administered Via an Inhaled Route in Healthy Female Volunteers Phase 1
Completed NCT04201665 - EMG for Uterotonic Efficiency Estimation N/A
Terminated NCT03246919 - Ideal Time of Oxytocin Infusion During Cesarean Section Phase 4
Not yet recruiting NCT05501106 - Reducing Postpartum Hemorrhage After Vaginal Delivery N/A
Completed NCT05429580 - Prophylactic Tranexamic Acid Use After Vaginal Delivery N/A
Terminated NCT03064152 - Rotational Thromboelastometry for the Transfusion Management of Postpartum Hemorrhage After Vaginal or Cesarean Delivery N/A
Recruiting NCT05382403 - Novel Vacuum-Induced Hemorrhage Control for Postpartum Hemorrhage N/A
Not yet recruiting NCT02853552 - Misoprostol as First Aid Measure to Address Excessive Postpartum Bleeding Phase 4
Completed NCT03344302 - Oxytocin Administration During Cesarean Section Phase 4
Completed NCT02910310 - Introduction of UBT for PPH Management in Three Countries N/A